Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29155234 | 1.00 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL29155289 | 0.96 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL4287048 | 0.91 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1EPHX1 | |
| SCHEMBL1551516 | 0.81 | OPRL1 (0.52) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL2675725 | 0.79 | RPS6KB1 (0.46) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL12052181 | 0.79 | RPS6KB1 (0.46) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL2790915 | 0.79 | RPS6KB1 (0.46) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL24334076 | 0.78 | RPS6KB1 (0.32) | OPRM1OPRD1OPRK1OPRL1RPS6KB1 | |
| SCHEMBL8249942 | 0.75 | RPS6KB1 (0.46) | OPRM1OPRD1OPRK1OPRL1DPP4 | |
| SCHEMBL12052190 | 0.75 | RPS6KB1 (0.46) | OPRM1OPRD1OPRK1OPRL1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | claimed |
| EP-2513061-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | claimed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | claimed |
| WO-2010045948-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-04-29 | — | — | WO | claimed |
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415373-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| EP-2513061-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-11-24 | — | — | US | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| WO-2010045948-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010045948-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288120-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNK3, KCNQ3, KCNN3 | OPRM1 761/4885OPRD1 403/4885OPRK1 174/4885 |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | KCNK3, GRIK3, KCND3 | OPRM1 1140/4885OPRD1 1034/4885OPRK1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.